Logo image of FULC

FULCRUM THERAPEUTICS INC (FULC) Stock Fundamental Analysis

USA - NASDAQ:FULC - US3596161097 - Common Stock

7 USD
+0.01 (+0.14%)
Last: 9/12/2025, 8:00:01 PM
7 USD
0 (0%)
After Hours: 9/12/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to FULC. FULC was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for FULC as it has an excellent financial health rating, but there are worries on the profitability. FULC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FULC has reported negative net income.
In the past year FULC has reported a negative cash flow from operations.
FULC had negative earnings in each of the past 5 years.
FULC had a negative operating cash flow in each of the past 5 years.
FULC Yearly Net Income VS EBIT VS OCF VS FCFFULC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

FULC has a better Return On Assets (-4.25%) than 71.94% of its industry peers.
FULC has a better Return On Equity (-4.54%) than 77.04% of its industry peers.
Industry RankSector Rank
ROA -4.25%
ROE -4.54%
ROIC N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
FULC Yearly ROA, ROE, ROICFULC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FULC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FULC Yearly Profit, Operating, Gross MarginsFULC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

9

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
FULC has less shares outstanding than it did 1 year ago.
The number of shares outstanding for FULC has been increased compared to 5 years ago.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FULC Yearly Shares OutstandingFULC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FULC Yearly Total Debt VS Total AssetsFULC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

FULC has an Altman-Z score of 13.49. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.
FULC's Altman-Z score of 13.49 is amongst the best of the industry. FULC outperforms 87.76% of its industry peers.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.49
ROIC/WACCN/A
WACC9.93%
FULC Yearly LT Debt VS Equity VS FCFFULC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 24.42 indicates that FULC has no problem at all paying its short term obligations.
FULC has a Current ratio of 24.42. This is amongst the best in the industry. FULC outperforms 94.39% of its industry peers.
FULC has a Quick Ratio of 24.42. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 24.42, FULC belongs to the top of the industry, outperforming 94.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.42
Quick Ratio 24.42
FULC Yearly Current Assets VS Current LiabilitesFULC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for FULC have decreased strongly by -248.57% in the last year.
Looking at the last year, FULC shows a very strong growth in Revenue. The Revenue has grown by 2752.05%.
Measured over the past years, FULC shows a very strong growth in Revenue. The Revenue has been growing by 61.03% on average per year.
EPS 1Y (TTM)-248.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.18%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -21.59% on average over the next years. This is quite bad
FULC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -9.72% yearly.
EPS Next Y-430.28%
EPS Next 2Y-135.14%
EPS Next 3Y-68.07%
EPS Next 5Y-21.59%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FULC Yearly Revenue VS EstimatesFULC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
FULC Yearly EPS VS EstimatesFULC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FULC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FULC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FULC Price Earnings VS Forward Price EarningsFULC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FULC Per share dataFULC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as FULC's earnings are expected to decrease with -68.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-135.14%
EPS Next 3Y-68.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FULC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (9/12/2025, 8:00:01 PM)

After market: 7 0 (0%)

7

+0.01 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners95.45%
Inst Owner Change6.28%
Ins Owners0.63%
Ins Owner Change-0.01%
Market Cap378.63M
Analysts80
Price Target11.29 (61.29%)
Short Float %10.97%
Short Ratio8.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.99%
Min EPS beat(2)5.34%
Max EPS beat(2)6.63%
EPS beat(4)4
Avg EPS beat(4)8.2%
Min EPS beat(4)5.34%
Max EPS beat(4)15.39%
EPS beat(8)8
Avg EPS beat(8)872.5%
EPS beat(12)11
Avg EPS beat(12)585.52%
EPS beat(16)13
Avg EPS beat(16)439.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)46.23%
EPS NQ rev (1m)-1.73%
EPS NQ rev (3m)18.4%
EPS NY rev (1m)2.12%
EPS NY rev (3m)1.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.73
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS1.48
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -4.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.95%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.42
Quick Ratio 24.42
Altman-Z 13.49
F-Score5
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)40.72%
Cap/Depr(5y)49.27%
Cap/Sales(3y)16.46%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-248.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.18%
EPS Next Y-430.28%
EPS Next 2Y-135.14%
EPS Next 3Y-68.07%
EPS Next 5Y-21.59%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-9.72%
EBIT growth 1Y82.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.96%
EBIT Next 3Y-40.92%
EBIT Next 5YN/A
FCF growth 1Y30.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.81%
OCF growth 3YN/A
OCF growth 5YN/A